Guilty as charged B-RAF is a human oncogene by Garnett, Mathew J. & Marais, Richard
CANCER CELL : OCTOBER 2004 · VOL. 6 · COPYRIGHT © 2004 CELL PRESS 313
Introduction
There are three RAF paralogs in humans: A-RAF, B-RAF, and
C-RAF (also called Raf-1) (Marais and Marshall, 1996). These
serine/threonine protein kinases are components of a con-
served signaling pathway downstream of the membrane-bound
small G protein RAS, which is activated by growth factors, hor-
mones, and cytokines (Robinson and Cobb, 1997). RAS stimu-
lates RAF activation, which then activates a second protein
kinase called MEK, which in turn activates a third protein kinase
called ERK (Figure 1). ERK regulates gene expression,
cytoskeletal rearrangements, and metabolism to coordinate
responses to extracellular signals and regulate proliferation, dif-
ferentiation, senescence, and apoptosis. This pathway is hyper-
activated in ?30% of cancers (Hoshino et al., 1999) with
activating mutations in RAS occurring in approximately
15%–30% of cancers (Bos, 1989), and recent data has shown
that B-RAF is mutated in about 7% of cancers (Davies et al.,
2002), identifying it as another important oncogene on this
pathway.
A short course on RAF regulation
RAF proteins share three conserved regions; CR1 and CR2 in
the N terminus (Figure 2) are largely regulatory, whereas CR3
at the C terminus encompasses the kinase domain. RAF regu-
lation is complex and involves many steps (for reviews see
Avruch et al., 2001; Mercer and Pritchard, 2003). In its simplest
form, RAS recruits cytosolic RAF to the plasma membrane for
activation (Figure 1), with one of the essential steps being the
phosphorylation of two amino acids (T598 and S601 of B-RAF;
see Note at the end of the main text for amino acid numbering
used in this review) within the activation segment of the kinase
domain (Figure 2) (Zhang and Guan, 2000). Phosphorylation of
a motif called the negative-charge regulatory region (N region)
is also required, and critically, this region has important conse-
quences for the differential regulation of the RAF isoforms.
S338 and Y341 of C-RAF, and similarly S299 and Y302 of A-
RAF, must be phosphorylated for maximal activation (Figure 2)
(Fabian et al., 1993; Mason et al., 1999). In B-RAF, S445 (equiv-
alent to S338 of C-RAF) is constitutively phosphorylated, and
the equivalent of Y341 is replaced by an aspartic acid (D448;
Figure 2). Thus, unlike A-RAF and C-RAF, the N region of B-
RAF carries a constitutive negative charge, and so B-RAF is
primed for activation, and this occurs when it is recruited to the
plasma membrane for activation segment phosphorylation. By
contrast, C-RAF and A-RAF activation is more complex,
because, like B-RAF, they also require membrane recruitment
and activation segment phosphorylation, but in addition, they
require N region phosphorylation.
The A to Z of B-RAF mutations
The highest incidence of B-RAF mutations is in malignant
melanoma (27%–70%), papillary thyroid cancer (36%–53%),
colorectal cancer (5%–22%), and serous ovarian cancer
(?30%), but they also occur at a low frequency (1%–3%) in a
wide variety of other cancers (Table 1). Over 40 different mis-
sense mutations in B-RAF, involving 24 different codons, have
been identified (Figure 2). Most mutations are extremely rare,
accounting for 0.1%–2% of all cases. However, a thymidine to
adenosine transversion at nucleotide 1796, converting valine
599 (V599) to glutamate predominates (Davies et al., 2002). It
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RAF proteins are components of a conserved signaling pathway that regulates cellular responses to extracellular signals.
Despite over 20 years of research into the regulation and function of the RAF proteins, it was only realized recently that the B-
RAF isoform is mutated at a high frequency in human cancer. Here we review the rapid progress made in our understanding
of B-RAF as an oncogene and of its role in cancer.
Figure 1. The RAS-ERK signaling pathway
The classical RAS-ERK signaling pathway is depicted. Growth factors bind
to and activate receptor tyrosine kinases (RTKs), which, through a series of
adaptor proteins and exchange factors, stimulate RAS activation. RAS pro-
teins are attached to the inner surface of the plasma membrane. In their
active form, they bind to and recruit RAF proteins from the cytosol to the
plasma membrane, which is where RAF is activated. RAF then phosphory-
lates and activates MEK, which in turn phosphorylates and activates ERK.
ERK phosphorylates proteins in the cytosol, and it also translocates to the
nucleus, where it phosphorylates proteins such as transcription factors. The
RTKs, RAS, and RAF are highlighted in red to reflect the fact that they are all
mutated in cancer.
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accounts for most (over 90%) of the mutations in melanoma and
thyroid cancer and for a high proportion of those in colorectal
cancer, but is comparatively rare in non-small cell lung cancer
(Fukushima et al., 2003; Kimura et al., 2003; Kumar et al., 2003;
Nikiforova et al., 2003; Brose et al., 2002; Davies et al., 2002;
Rajagopalan et al., 2002; Yuen et al., 2002). It is worth noting
that in the absence of the V599E substitution, B-RAF mutations
in cancer would be rather rare. V599 can also be mutated to
other residues (Table 1), although at a much lower frequency
(0.1% to 2%). Presumably this is because, although their activi-
ties are similar to that of V599EB-RAF (Wan et al., 2004), they
arise through tandem nucleotide changes that are very rare.
This is supported by the observation that a tandem mutation
that generates V599EB-RAF is also very rare (<0.1%) (Houben et
al., 2004).
The pattern of B-RAF mutations raises two important ques-
tions. First, why are B-RAF mutations common in some cancers
but not in others? In part, the answer comes from the observa-
tion that B-RAF mutations occur in many of the same cancers in
which RAS is mutated, but concomitant mutations are extreme-
ly rare (Davies et al., 2002; Rajagopalan et al., 2002; Singer et
al., 2003).This is elegantly illustrated in papillary thyroid cancer,
where 66% of tumors have activating mutations in RET (a
receptor tyrosine kinase that signals through RAS), RAS, or B-
RAF, but strikingly, there is no coincidence between them
(Kimura et al., 2003).Thus, B-RAF mutations appear to occur in
cancers where there is strong selection for aberrant ERK sig-
naling, and the mutations causing this can occur at different lev-
els within the pathway. The biology of cancer precursor cells
may also provide a partial answer to the question. Melanocytes
and thyrocytes are neuronal in origin and stimulation with
appropriate hormones elevates their intracellular cAMP levels,
activating B-RAF and inducing proliferation (Busca et al., 2000;
Iacovelli et al., 2001). The interplay between B-RAF, cAMP, and
proliferation in these cells may provide strong selection for B-
RAF mutations, particularly V599EB-RAF.
The second question is: why do V599 mutations predomi-
nate? The selection does not appear to be based on catalytic
activity, because mutants such as G468AB-RAF have similar activ-
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Figure 2. Cancer-associated B-RAF mutations
The structure of B-RAF is shown schematically.
The three regions that are conserved in all RAF
proteins, CR1 (blue), CR2 (orange), are CR3
(straw) are shown. The kinase domain is encom-
passed within CR3. The amino acid sequence of
the N region, the glycine-rich loop, the catalytic
loop, and the activation segment (single amino
acid code) for B-RAF, C-RAF, and A-RAF are
aligned above the schematic. The yellow bars
highlight residues whose phosphorylation is
required for kinase activity. The residues that are
mutated in B-RAF in cancer are shown in bold,
with the amino acid substitutions above the
sequence. In addition, mutated residues out-
side these core regions are shown below the
schematic, with the amino acids that they are
converted to below them. The mutated
residues are color-coded for their effect on B-
RAF kinase activity. Activating substitutions are
shown in green, those that impair B-RAF kinase
activity are in red, and untested mutants are in
blue. Amino acids in A-RAF and C-RAF that are
conserved in B-RAF are indicated by a dot.
Figure 3. B-RAF kinase domain structure
The structure of the B-RAF kinase domain is shown (residues 447725). For
clarity, BAY43-9006, the inhibitor that B-RAF was crystallized with, has been
omitted. 
A: Important catalytic and structural features. The small lobe, large lobe,
and catalytic cleft are indicated. The N region is colored rust, with the inter-
action that occurs between D447 of this region and R505 of the αC-helix
being depicted by the red dashed line. The glycine-rich loop is green, the
catalytic loop is blue, the activation segment is magenta, and the DFG
and APE motifs are purple. A portion of the activation segment is disor-
dered and is indicated by the dashed magenta line. T598, the activation
segment phosphorylation site, is colored yellow. 
B: Mutations in B-RAF in cancer. The same views shown in A are presented,
but with the mutated residues colored red or orange (alternate colors are
used for clarity, but have no additional significance).
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ity to V599EB-RAF and are also generated through a single
nucleotide substitution, but account for less than 1% of muta-
tions (Davies et al., 2002). The high incidence of V599E muta-
tions in melanoma, a disease whose only risk factor is exposure
to sunlight (De Vita et al., 2001), suggests that this mutation is
induced by ultraviolet (UV) light. Indeed, V599E mutations are
absent in mucosal melanoma (Edwards et al., 2004) and are
also rare in melanomas from regions of sun-protected skin
(Maldonado et al., 2003). However, the T>A transversion asso-
ciated with V599E mutations is distinct from the C>T or
CC>>TT pyrimidine dimer mutations common to UV-induced
DNA damage (Daya-Grosjean et al., 1995). Moreover, B-RAF
mutations are not found in other forms of skin cancer such as
basal or squamous cell carcinomas, and UV exposure is clearly
not responsible for the V599E mutations in colorectal, thyroid,
and ovarian cancers. Thus, although the V599E mutations may
be an indirect consequence of UV exposure in melanoma, in
other cancers, it is presumably the context of the DNA sur-
rounding this codon combined with the biology and/or the envi-
ronment of the cells that accounts for the high frequency of this
mutation.
A molecular understanding of B-RAF mutations
Our understanding of B-RAF regulation was greatly increased
recently when the crystal structure of the B-RAF kinase domain
bound to the small molecule inhibitor BAY43-9006 was solved
(Wan et al., 2004). The kinase adopts the overall fold typical of
active kinases, with a small and large lobe separated by a cat-
alytic cleft (Figure 3A). The N region aspartic acid at position
447 helps to stabilize the small lobe.The glycine-rich loop, iden-
tified by the GXGXXG motif (G = glycine, X = variable) which
clamps ATP into the catalytic cleft (Johnson et al., 1998) is well
defined (Figures 2 and 3A). A portion of the activation segment,
a flexible region between the conserved DFG and APE motifs
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Table 1. Cancer-associated mutations of B-RAF
Amino acida Coding variantb Frequencyc Cancer typed (incidence)
M116 R 0.1 Mel (1) 
I325 T 0.1 Breast (1)
K438 Q, T 0.2 Lung (2)
T439 P 0.1 Lung (1)
V458 L 0.1 Lung (1)
R461 I 0.1 Colo (1)
I462 S 0.1 Colo (1)
G463 E, V, R 0.5 Colo (3), liver (1), ova (1)
G465 A, E, R, V 0.9 Mel (7), lung (2) 
F467 C 0.1 Colo (1)
G468 A, E, R, S, V 1.9 Mel (4), leukemia (4), colo (3), nhl (3), liver (2), lung (2), bar (1)
K474 E 0.1 Mel (1)
N580 S 0.1 Colo (1)
E585 K 0.1 Ova (1)
D586 A 0.1 Colo (1)
D593 G, K, V 1.0 Colo (6), stom (2), mel (1), nhl (1)
F594 L 0.3 Colo (2), liver (1)
G595 R 0.2 Colo (2)
L596 Q, R, S, V 0.8 Mel (3), lung (3), liver (1), ova (1)
T598 I 0.1 Colo (1)
T598-insertion Two amino acid insertion (T-T) 0.1 Mel (1)
V599 D, E, G, K, M, R 91e Mel (442), thy (187), colo (179), ova (24), liver (11), sarcoma (7), stomach (5), 
glioma (4), Bar (2), breast (1), epen (1), lung (1)
V599-insertion/ Six amino acids (V599-K604) 0.1 Mel (1)
deletion replaced by an aspartic acid
K600 E, N 1.0 Thy (4), mel (3), colo (3)
R681 Q 0.1 Endo (1)
A727 V 0.1 ALL (1)
aThe mutations described in B-RAF in cancer are listed in column 1.
bThe residues they are mutated to (coding variant) are shown in column 2.
cIn column 3, the frequency with which each residue is mutated with respect to reported B-RAF mutations is provided. These data are compiled from 37
publications with over 900 B-RAF mutation-positive tumor samples and cell lines. Due to editorial limitations we are unable to cite all the references used to
compile this table and we apologize to the authors of those papers not cited. For a detailed description of the B-RAF mutations in cancer, please see the
COSMIC website (www.sanger.ac.uk/genetics/CGP/cosmic/). 
dFinally, in column 4, the occurrence of each mutation in specific cancers is shown: mel, melanoma; colo, colorectal; thy, thyroid; ova, ovarian; endo,
endometrial; nhl, non-Hodgkins lymphoma; bar, Barrets adenocarcinoma; epen, ependymoma; ALL, acute lymphoblastic leukemia. Incidence refers to
the total number of times the mutations at the indicated position have been identified in that cancer type. 
eAltogether, the V599 substitutions account for 91% of the mutations in cancer. However, the V599E mutation accounts for approximately 95% of these, and
therefore approximately 86% of all mutations in cancer.
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(Figures 2 and 3A) that is likely to facilitate substrate recognition
and to position key catalytic residues (Johnson et al., 1998), is
also well defined.
Intriguingly, there is a distinctive hydrophobic interaction
between the glycine-rich loop and activation segment of B-RAF,
and this displaces the DFG motif to a position that is incompati-
ble with catalysis (Figure 3A). As mentioned above, phosphory-
lation of T598 within the activation segment is essential for
B-RAF activation, and this residue is at the interface of the
glycine-rich loop/activation segment interaction domain. Its
phosphorylation is predicted to disrupt the interaction, displac-
ing the activation segment and thereby permitting the DFG motif
to adopt the active conformation (Wan et al., 2004), explaining
how activation segment phosphorylation stimulates B-RAF
kinase activity. Since the kinases that phosphorylate T598 seem
to be at the membrane, the structure also explains why B-RAF
recruitment to the plasma membrane is necessary.
Furthermore, it partly explains why N region charge is neces-
sary for B-RAF activity and provides a rational explanation for
why N region phosphorylation of A-RAF and C-RAF is
required—presumably it also stabilizes the small lobe. It proba-
bly also explains why A-RAF and C-RAF are not mutated in can-
cer (Davies et al., 2002; Fransen et al., 2004), despite the fact
that many of the residues mutated in B-RAF are conserved
(Figure 2). In the absence of N region-mediated small lobe sta-
bilization, substitutions that reorganize the activation segments
of A-RAF and C-RAF will be insufficient to induce the active
conformation, and so they will not be selected in cancer.
The majority of the mutations that occur in cancer activate
B-RAF, as has been shown by direct measurements of their
abilities to phosphorylate MEK in vitro and stimulate ERK sig-
naling in vivo (Figure 2) (Davies et al., 2002; Ikenoue et al.,
2003, 2004; Houben et al., 2004; Wan et al., 2004). However,
the activities of the mutants range from 1.3- to 700-fold relative
to WTB-RAF, and again, the structure explains the underlying
mechanism. The mutations cluster to the glycine-rich loop and
activation segment and involve many of the residues that stabi-
lize the interaction between these regions (Figures 2 and 3)
(Wan et al., 2004). Importantly, many of these residues, such as
the glycines (G463, G465, and G468) of the glycine-rich loop,
the Asn (N580) of the catalytic loop, and the phenylalanine
(F594) of the DFG motif are highly conserved within the kinase
superfamily (Hanks and Hunter, 1995; Johnson et al., 1998).
This is because they serve key catalytic functions, and yet,
despite this, when mutated in B-RAF in cancer, they can be acti-
vating (Figure 2), although their levels of activity tend to be
lower than the mutants involving the nonconserved residues
(Wan et al., 2004). A unifying feature of the mutations is that
they disrupt the gycine-rich loop/activation segment interaction,
destabilizing the inactive conformation and stimulating B-RAF
activity up to 700-fold. However, since some of the mutations
involve important catalytic residues, the full activation potential
is not reached, and therefore some mutants have only modestly
increased kinase activity.
Any interpretation of RAF regulation based on the structure
must be considered in light of the fact that BAY43-9006 may
induce an inactive conformation in the protein that does not
reflect the “native” inactive conformation of B-RAF. However, the
model does provide a satisfactory explanation of why activation
segment phosphorylation is necessary for activity and of how
the mutants activate B-RAF. It also explains why the mutants
are selected for in cancer and why they cluster to the glycine-
rich loop and activation segment. Thus, it seems that BAY43-
9006 induces a conformation in B-RAF that does reflect the
normal inactive state, and hence the structure provides a great
deal of insight into how B-RAF is regulated.
It should also be noted that the structure does not reveal
how the kinase domain interacts with the rest of the molecule,
and intriguingly, some of the mutations do not appear to involve
amino acids involved in stabilizing the glycine-rich loop/activa-
tion segment interaction. For example, E585, D586, and R681
are all at the “back” of the kinase domain (Figure 3B). They
appear to define a large surface that is remarkably similar to
one found in the tyrosine kinase Abl and which is responsible for
its negative regulation through an intramolecular interaction
with the noncatalytic N-terminal domains (Nagar et al., 2003).
This provides an exciting possibility that B-RAF is regulated by
its N terminus through a similar mechanism, and these muta-
tions may disrupt this interaction. Another example is A727,
which is within a 14-3-3 binding site C-terminal to the kinase
domain (Figure 2); it is not clear how its mutation to valine acti-
vates B-RAF. Finally, K438 and T439 are outside the kinase
domain in a region of B-RAF that is implicated in negative regu-
lation by protein kinase B (Figure 2) (Guan et al., 2000).
Presumably, some of the mutants destabilize the inactive con-
formation through alternative mechanisms, possibly by disrupt-
ing intramolecular interactions, or by affecting negative
regulation by other pathways, demonstrating that B-RAF can be
activated by multiple mechanisms, some of which are not fully
understood.
The biology of B-RAF in cancer
V599EB-RAF is one of the most active mutants, its in vitro kinase
activity being ?500 fold greater than that of WTB-RAF (Wan et
al., 2004). In NIH3T3 cells and murine melanocytes, V599EB-RAF
stimulates constitutive ERK signaling, induces proliferation and
transformation, and allows these cells to grow as tumors in
nude mice (Davies et al., 2002; Ikenoue et al., 2003, 2004;
Houben et al., 2004; Wan et al., 2004; Wellbrock et al., 2004).
These data show that B-RAF is an oncogene. However, V599EB-
RAF is detected in a high proportion of naevi (Pollock et al.,
2003; Yazdi et al., 2003), benign melanocytic skin lesions in
R E V I E W
Figure 4. B-RAF signaling in cancer
The signaling pathways stimulated by B-RAF mutants in cancer are shown.
The impaired activity mutants cannot signal to MEK directly, but do so by
activating C-RAF. The activated mutants signal to MEK directly, and
although they can also activate C-RAF, this does not appear to be neces-
sary for signaling to MEK. D593VB-RAF does not signal to either MEK or C-RAF
and may signal to other unknown pathways. Alternatively, it could act as a
dominant-negative to suppress MEK activation in some cellular contexts.
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which the cells are thought to be senescent, and it is also found
in premalignant colon polyps and the early Duke’s stages (A/B)
of colorectal cancer (Rajagopalan et al., 2002; Yuen et al.,
2002). Thus, B-RAF activation occurs early in tumorigenesis
and may be a founder event, but by itself it is not sufficient to
induce cancer. Finally, V599EB-RAF also activates NF-κB
(Ikenoue et al., 2003, 2004) and protects cells from apoptosis
(Hingorani et al., 2003; Karasarides et al., 2004), both of which
may be important for transformation.
Many of the other mutants also transform cells and so
appear, like V599EB-RAF, to be classically activated oncogenes
(Davies et al., 2002; Ikenoue et al., 2003, 2004; Houben et al.,
2004; Wan et al., 2004). However, there is a group of mutants
that have impaired kinase activity relative to WTB-RAF (Figure 2)
(Ikenoue et al., 2003, 2004; Houben et al., 2004; Wan et al.,
2004). While their lack of activity is not surprising, because they
involve the important catalytic residues G465 (the second Gly of
the glycine-rich loop) and G595 (the Gly of the DFG motif), what
is surprising is that they can still stimulate ERK signaling in cells
because they activate wild-type C-RAF, which then activates
MEK (Figure 4) (Wan et al., 2004). Indeed, depletion of C-RAF
in cells that express these mutants blocks ERK activity (Wan et
al., 2004), demonstrating the dependence of the mutants on C-
RAF for signaling down this pathway. These mutants are also
predicted to adopt the active conformation, but presumably can-
not phosphorylate MEK due to additional disruptions induced
by their specific substitutions. However, they can associate with
C-RAF and presumably transmit a signal to it because they are
in the active conformation. Thus, it seems that irrespective of
their kinase activity, most of the B-RAF mutants stimulate ERK
signaling in cells.
To stimulate proliferation, the level of ERK signaling must be
carefully modulated, because if it is too strong, cells will stop
cycling and differentiate or senesce (Marshall, 1995; Kerkhoff
and Rapp, 1996; Sewing et al., 1997; Woods et al., 1997). This
may explain why different levels of activation are seen in the B-
RAF mutants. Some of the rare mutants may occur in contexts
that select for weaker B-RAF signaling as a secondary event to
an existing mutation already in the pathway. This model is sup-
ported by the observation that some rare B-RAF mutants are
coincident with RAS mutations, suggesting that they cooperate
to carefully modulate ERK signaling (Davies et al., 2002; Yuen
et al., 2002). Indeed, some cancer cell lines expressing the rare
B-RAF mutants still require RAS for proliferation, whereas cells
expressing V599EB-RAF do not (Davies et al., 2002). Presumably,
V599EB-RAF does not occur with RAS mutations, because their
combined signaling is incompatible with proliferation.
Finally, the most enigmatic mutations are those involving
D593, the aspartate of the DFG motif (Figure 2). D593VB-RAF
cannot phosphorylate MEK in vitro and does not activate C-
RAF, ERK, or NF-κB in cells (Ikenoue et al., 2003; Wan et al.,
2004). It is not surprising that D593VB-RAF is a loss-of-function
mutant, because D593 is a key catalytic residue (Hanks and
Hunter, 1995; Johnson et al., 1998), and the other substitutions
at this position are also likely to be inactive. However, together,
they account for ?1% of all B-RAF mutants, too common for a
random event, particularly as similar mutations are not found in
C-RAF or A-RAF. Their role in cancer is unclear, but they could
act as dominant-negative regulators of RAS to suppress ram-
pant ERK signaling (Figure 4), and it is worth noting that three
out of the ten D593 mutants occurred coincident with mutant
RAS (Yuen et al., 2002; Houben et al., 2004), significantly more
frequently than other mutants. However, it is also possible that
these mutants actually function in completely different pathways
in cancer, but currently, there are no candidate B-RAF effectors
of these putative pathways, and presumably this signaling
would be independent of B-RAF kinase activity.
Therapeutic implications
Studies with RNA interference have demonstrated that deplet-
ing oncogenic B-RAF in cancer cells reduces ERK activity,
inhibits proliferation, and induces apoptosis (Hingorani et al.,
2003; Karasarides et al., 2004). The C-RAF inhibitor BAY43-
9006 also inhibits B-RAF in vitro and in vivo, and provides some
therapeutic benefit in tumor xenografts of melanoma cells
expressing oncogenic B-RAF (Karasarides et al., 2004).
However, in phase II clinical trials, when administered to
patients as a monotherapy for melanoma, BAY43-9006 has lim-
ited antitumor activity, and it is currently being tested in combi-
nation with other agents (T. Eisen, personal communication).
Until the data analysis is complete, it is premature to try to
explain why the monotherapy trials in melanoma have been dis-
appointing, and although it sounds a note of caution, the pre-
clinical work has shown that B-RAF is an important therapeutic
target, and there is considerable interest in developing potent B-
RAF inhibitors.
Initial efforts are likely to focus on developing agents that
inhibit V599EB-RAF, because it is the most common mutant, but
as many of the mutations activate B-RAF through a common
mechanism, it is hoped that these agents will inhibit most or all
of the mutants. However, previous experience warns that this
may not be the case. The tyrosine kinase Abl plays a major role
in the etiology of chronic myeloid leukaemia (CML). Imatinib is a
small molecule inhibitor of Abl that has been used to treat CML
with spectacular results, but initial excitement is tempered by
clinical resistance to treatment driven by the occurrence of point
mutations in Abl that block imatinib binding (Gorre et al., 2001;
Shawver et al., 2002). Since B-RAF can tolerate many different
point mutations within its kinase domain, it is possible that sin-
gle agents will fail to inhibit all mutants, and this may also pro-
vide a mechanism for clinical resistance to develop. To preempt
this likely occurrence, it will be desirable to develop an arsenal
of anti-B-RAF drugs with different modes of action. Again, Abl
provides the paradigm, because the compound BMS-354825,
which binds to Abl through an alternative mechanism, can inhib-
it 14 out of 15 imatinib-resistant Abl mutants (Shah et al., 2004).
Another complication of B-RAF is the finding that the impaired
activity mutants can activate ERK via C-RAF.This suggests that
agents that inhibit B-RAF, but allow the active conformation to
persist, could stimulate ERK signaling via C-RAF. In practice, it
is likely that most B-RAF inhibitors will also inhibit C-RAF, there-
by blocking signaling through this pathway whether it arises
directly from B-RAF, from cryptic C-RAF activation, or by other
upstream events.
Conclusions
Rapid progress has been made in our understanding of the B-
RAF mutations in cancer, both at the molecular and biological
levels. We understand how phosphorylation regulates B-RAF
and also how many of the mutations stimulate its activity.
However, further work is required to understand some of the
rare mutations that appear to activate B-RAF through distinct
mechanisms; no doubt this understanding will reveal more
about how WTB-RAF is regulated. The majority of the mutants
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signal to ERK either directly through MEK or indirectly through
C-RAF (Figure 4). For V599EB-RAF, this signaling stimulates pro-
liferation and protects cells from apoptosis. Presumably, ERK
signaling will also be important for the biological functions of the
other mutants, but it is possible that the individual mutants will
have different biological outputs. As noted, some of the mutants
require RAS to stimulate cell growth, whereas others do not,
either reflecting differences in the mutants themselves or differ-
ences in the cellular context in which they occur. Thus, although
we may expect all B-RAF mutants to have more-or-less similar
outputs, a closer examination of a range of mutants may reveal
important differences in the biological functions between them.
Furthermore, understanding how this differs from WTB-RAF sig-
naling will provide further insight into the biological functions of
B-RAF signaling in normal cells.
Another area that needs greater understanding is the role
that C-RAF plays in mediating ERK signaling in cells with B-
RAF mutations. It will be important to determine how mutant B-
RAF activates C-RAF and what the biological outputs from this
signaling are, to define the role that C-RAF plays in the onco-
genic activity of the mutants, and to determine whether WTB-
RAF also activates C-RAF in normal cells. It will also be
important to investigate how B-RAF regulates apoptosis. B-RAF
has been validated as an important therapeutic target because
its inhibition blocks proliferation and induces apoptosis in can-
cer cells, and yet, we understand very little of the regulation of
apoptosis by this isoform. Ultimately, it will be desirable to devel-
op an arsenal of potent B-RAF inhibitors to allow us to test the
importance of this oncogene in the clinical setting and to offer
novel strategies for treating cancers that harbor mutations in
this gene.
Note
The original B-RAF sequence deposited on the NCBI web site
was missing a codon (three nucleotides) in the region encoding
for the amino acids 31 and 32 (see http://www.ncbi.nlm.nih.gov/
entrez/sutils/girevhist.cgi/girevhist.cgi?val=NM_004333). The
corrected sequence is therefore one amino acid longer than
originally thought and all amino acids after the alanine at 33 are
displaced by one position. For example, T598 and S601 are
actually T599 and S602, and the common valine mutation is
actually V600 and not V599. However, in order to avoid confu-
sion with original published data, here we use the original, if
incorrect, numbering.
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